Aquapharm Biodiscovery nets $8.3M for marine-based antibiotics
Aquapharm Biodiscovery, a Scottish biotech aiming to discover new antibiotics and antioxidants from marine organisms, raised $8.3 million (£4 million) in a second funding round (PDF). The company, based near Oban in the European Center for Marine Biotechnology, harvests and cultures marine microbes in order to screen them for new biochemicals that might serve as drugs or food and cosmetics additives.
Aescap Venture led the round, joined by Tate & Lyle Ventures, Scottish Enterprise, NESTA Investments and HIE Argyll and the Islands.
Next Story: Merck buys cardio-drug maker NovaCardia for $350M
Previous Story: InfoNgen, Netvibes for finance junkies
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.